Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Latanoprost
Drug ID BADD_D01251
Description Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.[A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. Another benefit latanoprost is that it can be administered once a day.[A184490]
Indications and Usage For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Marketing Status Prescription; Discontinued
ATC Code S01EE01
DrugBank ID DB00654
KEGG ID D00356
MeSH ID D000077338
PubChem ID 5311221
TTD Drug ID D0C6NM
NDC Product Code 90027-006; 68071-2376; 59762-0333; 47335-317; 24208-463; 63190-0710; 65326-004; 45542-1156; 0009-5172; 51927-4864; 42385-039; 55545-0462; 71684-0547; 45542-1159; 68071-4893; 12079-0475; 64980-516; 50090-1920; 61314-547; 51927-0091; 68245-0002; 71205-154; 65035-128; 51552-1385; 17478-625; 46144-156; 65862-872; 40016-001; 71052-041; 61919-112; 65727-026; 61556-050; 65427-007; 81997-001; 68071-4650; 51927-0090; 24002-0018; 54893-0010; 10695-048; 0013-8303; 82231-111; 68071-4612; 70069-421
Synonyms Latanoprost | PhXA34 | PHXA41 | Xalatan
Chemical Information
Molecular Formula C26H40O5
CAS Registry Number 130209-82-4
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dementia17.03.01.001; 19.20.02.0010.000225%Not Available
Depressed mood19.15.02.0010.000450%Not Available
Depression19.15.01.001--
Dermatitis23.03.04.0020.000225%Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.0010.000338%Not Available
Diabetic retinopathy05.07.01.002; 24.03.07.004; 14.07.01.002; 06.10.02.0020.000225%Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.0020.000675%Not Available
Discomfort08.01.08.0030.000338%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug hypersensitivity10.01.01.0010.004052%Not Available
Dry eye06.08.02.0010.003264%
Dry mouth07.06.01.0020.000338%
Dry throat22.02.05.004; 07.06.01.0050.000450%Not Available
Dysgeusia17.02.07.003; 07.14.03.0010.000450%
Dyskinesia17.01.02.0060.000225%
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.0040.000450%
Dyspnoea22.02.01.004; 02.01.03.002--
Ectropion06.06.04.001; 23.07.05.0010.000225%Not Available
Eczema23.03.04.006--
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.0010.001688%Not Available
Erythema of eyelid23.03.06.006; 06.04.04.0030.000675%Not Available
Exophthalmos05.02.02.002; 06.09.04.0010.000225%Not Available
Eye allergy06.04.05.010; 10.01.03.0280.000675%Not Available
Eye burns12.01.04.010; 06.11.01.0030.000675%Not Available
Eye discharge06.04.05.0010.000901%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 10 Pages